Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

June 06, 2019 08:00 ET | Source: Spring Bank Pharmaceuticals, Inc.

Spring Bank Announces Presentation of Promising Results from Study Highlighting Immune-Activation with Inarigivir 400mg

HOPKINTON, Mass., June 06, 2019 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (Nasdaq: SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of...
May 28, 2019 08:00 ET | Source: Spring Bank Pharmaceuticals, Inc.

Spring Bank Pharmaceuticals to Present at Jefferies 2019 Global Healthcare Conference

HOPKINTON, Mass., May 28, 2019 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (Nasdaq: SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of...
April 29, 2019 07:00 ET | Source: Spring Bank Pharmaceuticals, Inc.

Spring Bank Pharmaceuticals Reports First Quarter 2019 Financial and Operational Results and Provides Corporate Update

ACHIEVE trial completed – inarigivir HBsAg reduction comparable to interferon but with significantly better tolerability profilePhase 2 co-administration study of inarigivir + nucleotide analogue...
April 12, 2019 06:00 ET | Source: Spring Bank Pharmaceuticals, Inc.

Spring Bank Announces Positive Results from the Recently Completed Phase 2 Chronic Hepatitis B ACHIEVE Trial and Additional Inarigivir Studies

Consistent reduction in HBV DNA demonstrated with higher inarigivir doses including in high viral burden HBeAg-positive patients 26% HBsAg responder population for all inarigivir doses showed mean...
April 10, 2019 16:01 ET | Source: Spring Bank Pharmaceuticals, Inc.

Spring Bank to Host a Conference Call to Discuss Inarigivir Data Presented at the International Liver Congress™ (EASL 2019)

HOPKINTON, Mass., April 10, 2019 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (Nasdaq: SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of...
March 28, 2019 08:00 ET | Source: Spring Bank Pharmaceuticals, Inc.

Spring Bank Announces Inarigivir Abstracts Accepted for Oral and Poster Presentations at The International Liver Congress™ (EASL 2019)

Full inarigivir (IRIG) 200mg cohort results to be presented as a late breaker oral presentation at General Session II and Award Ceremony I Poster presentation to describe the antiviral activity...
March 14, 2019 08:00 ET | Source: Spring Bank Pharmaceuticals, Inc.

Spring Bank Pharmaceuticals to Participate in Jefferies 2019 HBV Summit

HOPKINTON, Mass., March 14, 2019 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (Nasdaq: SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of...
March 11, 2019 06:30 ET | Source: Spring Bank Pharmaceuticals, Inc.

Spring Bank Pharmaceuticals Reports 2018 Fourth Quarter and Full-Year Financial Results and Corporate Highlights

Conference Call to be Held at 8:00 am Eastern TimeInarigivir Late-Breaker Abstract Accepted for Oral Presentation at EASL The International Liver Congress 2019 HOPKINTON, Mass., March 11, 2019 ...
March 04, 2019 16:01 ET | Source: Spring Bank Pharmaceuticals, Inc.

Spring Bank to Host Conference Call to Discuss Fourth Quarter and Fiscal Year 2018 Results on Monday, March 11

HOPKINTON, Mass., March 04, 2019 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (Nasdaq: SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of...
February 19, 2019 16:38 ET | Source: Spring Bank Pharmaceuticals, Inc.

Spring Bank Pharmaceuticals Appoints Atif Abbas, M.D., as Vice President, Head of Oncology & Immunology Clinical Development

HOPKINTON, Mass., Feb. 19, 2019 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (Nasdaq: SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of...